Hangzhou Derun Yucheng Biotechnology

Hangzhou Derun Yucheng Biotechnology is a clinical-stage biotechnology company headquartered in Hangzhou, China, dedicated to the development of innovative cell therapies for oncology. The company specializes in engineering CAR-T and TCR-T cells designed to effectively target and eliminate solid tumors, which remain a significant challenge for traditional immunotherapies. By utilizing proprietary technology platforms, Derun Yucheng focuses on improving the infiltration and survival of T cells within the tumor microenvironment. Their pipeline includes several candidates in the pre-clinical and early clinical stages targeting high-unmet-need indications such as liver and lung cancers. The firm is positioned as a key player in the rapidly evolving Chinese cell therapy landscape.